Calypte Only Company with Full Menu of Tests.

Solange sich das nicht signifikant in Umsatz- und Ertragszahlen niederschlägt, heißt das erstmal gar nichts bei Calypte.


Never argue with an idiot -- they drag you down to their level, then beat you with experience.  

Im Moment tut sich volumenmässig da gar nix mehr. Vom Kurs ausgesetzt werden se ja wohl nicht sein. Vielleicht ist es ja die Ruhe vor dem Sturm.
Grüße, ZN  

du willst es nicht wahr haben, was berichtet worden ist..

Im Vergleich mit der Vergangenheit hast du auch irgendwo Recht.

Ich Pers. werde Dr. George nicht mit Tony auf der selben Ebene sehen ; )

vertrauen oder nicht vertrauen ?

Ich vertraue Caly



Gruß

C.O  

 

 

 

 

 

hast ja nichts verstanden was CC anbelangt....

auch das der Plan angenommen wurde ist für dich negativ, denn du hast ja mehr verständniß als AMEX selbst..

Naja kann man nichts machen reicht halt nicht dein IQ


Gruß

C.O  

 

 

 

 

 

ich mich hier mal wieder über Calypte informieren,
was finde ich vor, nur Löschungen!
Was geht hier eigentlich ab?
Werden etwa andere Meinungen ünterdrückt,wenn ja ,würde ich das
unglaublich finden.
Da ich wenig Zeit habe mir alle Beiträge durchzulesen,
würde mir eine Kurzfassung zur derzeitigen Lage von Calypte
weiterhelfen.

Vielleicht kann mich ein überzeugter Calyaner aufklären.
Danke  

für dich aus dem SEC 10QSB Filing in übersicht:

CALYPTE BIOMEDICAL CORP filed this Form 10QSB on 08/15/05
Entire Document
Entire Subdocument
Page 7  


                CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES
             NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                            June 30, 2005 and 2004
                                  (unaudited)

(1)   The Company

Calypte  Biomedical  Corporation  (the "Company")  develops,  manufactures,  and
distributes  in vitro  diagnostic  tests,  primarily  for the diagnosis of Human
Immunodeficiency  Virus  ("HIV")  infection.   Historically,   the  Company  has
manufactured and marketed urine-based HIV-1 diagnostic screening tests and urine
and serum-based  Western Blot supplemental tests for use in laboratories,  which
it refers to as its "Legacy  Business."  Since the Company  began  marketing its
urine  diagnostic  testing  products  following  their  approval  by the FDA and
through the second  quarter of 2005,  its revenues have been almost  exclusively
generated  from  sales  of  these  products.   The  Legacy  Business  tests  are
manufactured in formats that make them most suitable for high-volume  laboratory
settings.

Over the last two years, however, the Company has been broadening its historical
focus to  include  other HIV tests,  such as a  blood-based  incidence  test and
various  rapid tests using other  specimens.  In the last  quarter of 2004,  the
Company  introduced its HIV-1 BED incidence EIA test (the "BED Incidence  Test")
that detects HIV-1 infections that have occurred within  approximately the prior
6 months  and that can be used by  public  health  agencies  to  identify  those
regions and the populations within them where HIV transmission is occurring most
recently.   The  Company  is   currently   focusing  on  the   development   and
commercialization of its new test products for the rapid detection of antibodies
to HIV-1 and HIV Type 2, a second type of HIV  ("HIV-2"),  in blood,  oral fluid
and urine  samples  using a lateral flow  dipstick  design (the  "HIV-1/2  Rapid
Tests")  and the  commercialization  of the BED  Incidence  Test on a  worldwide
basis.

Rapid tests  provide test  results in less than 20 minutes and are  particularly
suitable for  point-of-care  testing,  especially in lesser developed  countries
which lack the medical  infrastructure to support laboratory based testing.  The
Company  has  completed  field  trials  of its  HIV-1/2  Rapid  Tests  that have
validated its prototype  products.  The Company has recently  completed clinical
trials in Uganda and China and is currently  engaged in clinical trials in other
countries in pursuit of regulatory approvals for these tests.

In April 2005 the Company  announced its plans to restructure  its business (the
"Plan") to consolidate its domestic  operations and focus its capital  resources
on the global commercialization of the HIV-1/2 Rapid Tests and the BED Incidence
Test. As part of the Plan, the Company  announced its plans to  discontinue  its
production  of the Legacy  Business  products  manufactured  at its  facility in
Rockville,  Maryland  and to pursue  various  options  ranging  from selling the
Legacy  Business to  discontinuing  manufacturing  operations  at the  Rockville
facility pending a final determination of its disposition.

In  furtherance  of the Plan,  on April 18,  2005,  the Company  entered  into a
non-binding  letter of intent to sell the Legacy  Business to Maxim  Biomedical,
Inc. ("Maxim").  Effective May 1, 2005, the Company entered into a manufacturing
services and management agreement (the "Agreement") with Maxim pursuant to which
Maxim will  manufacture,  ship and perform  quality  control  procedures for the
Company  in  connection  with  the  Legacy  Business.  Under  the  terms  of the
Agreement,  Maxim has hired some of the Company's  ex-employees  and the Company
transferred its inventory to Maxim for use under the Agreement.  Pursuant to the
Agreement,  Maxim has the right, but not the obligation,  to purchase the assets
of the Legacy  Business  on terms to be  negotiated  between  the  parties.  The
Company  will remain  liable for its  Rockville  facility  and  equipment  lease
obligations;  however,  it expects to reduce its operating expenses through this
arrangement.  The Company  expects that by year-end its Legacy  Business will be
classified as a discontinued operation.

Additionally,  during the third quarter of 2005, the Company expects to complete
the transition of its corporate headquarters to the Portland, Oregon area, where
its research and development  operations are located.  During the second quarter
of 2005, the Company incurred  severance costs for certain personnel  terminated
at Rockville and accrued  severance costs for certain  administrative  personnel
not transitioning to Oregon.  The Company may also be liable for lease costs for
its California  offices  through July 2007 in the event it is unable to sublease
that facility.  The Company accrued approximately $535,000 in the second quarter
of  2005  for   transition-related   costs  resulting  from  its   restructuring
activities.  The Company also incurred  approximately $1.2 million of expense in
the second  quarter of 2005  related to the  transfer of its  inventory to Maxim
under the Agreement.

Upon successful completion of the transition of the Legacy Business, the Company
believes that it will have significantly reduced its monthly operating burn rate
as compared with historical  levels.  If it is unable to complete a sale, it may
incur costs to decommission the Rockville  facilities;  on-going  facility lease
costs at Rockville,  until and unless sub-lease opportunities are available, and
on-going lease or lease termination costs associated with leased equipment.  The
Company cannot currently estimate those costs, but the Company expects that they
would increase its cash burn rate in comparison with the sale alternative. Under
either scenario,  the revenue stream from the Company's Legacy Business products
will have been  eliminated and it will rely on revenues from the sale of its BED
Incidence Test and, following regulatory approvals, from the sale of its HIV-1/2
Rapid Tests internationally.


                                      7


 

merci!  

leider wird hier manipuliert und korrumpiert, dass einem die schuhe platzen. aber das wird noch anderen leuten auffallen...  

 

vielleicht raffst Du es jetzt. Selbst Dr. Udo Bromme weist dich diskret auf Caly schaumschlägerein hin.

im übrigen: eure up-move ist wohl wieder beendet bei 0,15$. klar, warum sollte es auch höher gehen. die zahlen waren grottenschlecht. der verlust 3-mal so hoch wie die umsätze. klar, weniger kosten filen an, caly hat ja auch anfang des q-2 68% seines personals entlassen...und trotzdem!!!! von der cashburn-quote von 500.000 seid ihr meilenweit weg. ihr liegt bei ca. 1.200.000 im monat.

wahnsinn, ein unding!!!

auch die dubiose verlängerung des amex-listings ist nur ein kurzer rettungsanker, da caly bei weiterer verschlechterung der wirtschaftslage jederzeit da listing entzogen bekommen kann...und das wird keine 18-monate bis zum verlust des lisitng dauern. es wird schneller gehen...allein bei der cash-burn-rate seid ihr ende september wieder ohne kapital. dabei sollten doch dieses jahr keine aktien mehr ausgegeben werden....komisch ne? schon wieder hat caly euch etwas falsches erzählt.

aber schön, dass sich kade aucxh mal wieder getraut hat zu posten...fragt sich nur wie lange...

zwergnase, ich hoffe für dich, dass du jetzt mit knappem gewinn rauskommst. das ding dreht nämlich schon wieder. zu erschütternd sind die fakten.

caly liegt auf dem sterbebett...und wird wohl nicht mehr entkommen...  

By: roy_hinkley
15 Aug 2005, 10:25 AM EDT
Msg. 68012 of 68072
Jump to msg. #
News Today


http://www.nasdaq.com/aspxcontent/...ket=Amex&pageName=Company%20News


Absolutely pathetic, no Chinese approval and no rapid sales to announce. No Maxim Biomedical sale either. Maybe later today.

I am curious about the $ 2,000,000 non cash
income. Could it be the suppliers and patent holders took a cash payoff of $ .35 - $ .50 on the dollar rather than risk it all as a HIV payable.
The mere $ 2,000,000 left in the bank after the $ 8,000,000 infusion in April makes it look that way.

Cash burn looks to still be well over a million a month so if that isn't corrected they will run out of cash at the end of this month. Gee I think I predicted that earlier didn't I?

Reckon Marr is "standing by" ready to dump another 5.5 million in? How far do you chase bad money with good?  

By: roy_hinkley
15 Aug 2005, 06:38 PM EDT
Msg. 68055 of 68072
Jump to msg. #
Really too funny Jonas

You really are one of the group of people that is "some of the people you can fool all of the time".

Read the 10Q. $ 2,000,000 in the bank on 6-30-2005 and rolling through money like a drunk sailor at over 1.2 million a month, not the $ 500,000 a month promised by Dr. George.

Here is what is currently owed by HIV:


Trade accounts payable $1,963 $1,652
Accrued royalties 277 355
Accrued salary, severance and vacation pay 711 1,192
Accrued interest 175 9
Accrued consulting contract expenses 1,176 803
Accrued liabilities under intellectual property
license agreements 244 1,686
Other 427 521  

By: roy_hinkley
16 Aug 2005, 08:08 AM EDT
Msg. 68068 of 68072
(This msg. is a reply to 68067 by i_gotta_take_a_crap.)
Jump to msg. #
Only Grumby could find a positive in a 10Q that was worse than could be imagined. They burned through 4 million in cash in last 3 months. Actually 6 million if you include the repayment of loan to Marr.

Magic Urine Test that pumpers have hailed as the "Holy Grail" is being backburnered in China and Africa.

Zero retail sales to date of any rapid test.

Still owe suppliers and patent holders over 2 million and Magic over 1 million. Cash runs out at end of this quarter.  

klinken Sie sich bitte ruhig öfters mal hier ein, damit wenigstens Neulinge von den hahnbüchenen Versprechungen Calys nicht mit in die Tiefe gerissen werden...